A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Novartis
Pfizer
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Enliven Therapeutics
Cancer Trials Ireland
University Health Network, Toronto
City of Hope Medical Center
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Tanta University
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Eli Lilly and Company
Ono Pharmaceutical Co., Ltd.
Servier
Shanghai Zhongshan Hospital
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Institut du Cancer de Montpellier - Val d'Aurelle
Ludwig Institute for Cancer Research
NSABP Foundation Inc
University of Massachusetts, Worcester
GSO Global Clinical Research BV
University of Utah
Gilead Sciences
TG Therapeutics, Inc.
M.D. Anderson Cancer Center
mAbxience Research S.L.
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
GlaxoSmithKline
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Centre, Singapore
Hoffmann-La Roche
Duke University
UNC Lineberger Comprehensive Cancer Center